Covid 19 Research using Clinical Trials (Home Page)
Report for D015212: Inflammatory Bowel Diseases NIH
(Synonyms: Inflammatory Bowe, Inflammatory Bowel, Inflammatory Bowel Di, Inflammatory Bowel Disease, Inflammatory Bowel Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated MeSH Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002037 | Inflammation of the large intestine HPO | 1.00 |
There is one clinical trial.
Clinical Trials
1 Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic
Multicenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cells
NCT04344249 IBD COVID MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine
Primary Outcomes
Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection
Measure: IgG and IgM anti SARS-CoV-2 Time: through study completion, an average of 2 year
Secondary Outcomes
Description: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
weight (Kg)
height (m)
ABO Group ....
Measure: Clinical factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
Description: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
ACCOMMODATION
HOUSING AREA
number of people at home ....
Measure: demographic factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
Description: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
Measure: pharmacologic factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
HPO Nodes
HP:0002037: Inflammation of the large intestine
Genes 56
TNFAIP3 SKIV2L NCF4 TCF4 LRBA SKIV2L TTC37 RFXAP ZAP70 RET IL6 MAP3K7 FAS FERMT1 RTEL1 FASLG CIITA CARMIL2 XIAP RASGRP1 CASP10 HLA-DRB1 PLCG2 FOXP3 F13A1 STAT1 IL10RA WAS WAS IL21 SLC9A3 MST1 RFXANK ZAP70 WIPF1 GPIHBP1 TGFB1 F13B POLA1 FAS IL10RB BACH2 ABCB1 HPS1 COG6 NLRC4 NOD2 HLA-B ARPC1B RFX5 GPR35 MASP2 IRGM PRKCD RIPK1 OPLAH Protein Mutations 1
R139C
Primary Outcomes
Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection
Measure: IgG and IgM anti SARS-CoV-2 Time: through study completion, an average of 2 yearSecondary Outcomes
Description: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. weight (Kg) height (m) ABO Group ....
Measure: Clinical factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearDescription: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. ACCOMMODATION HOUSING AREA number of people at home ....
Measure: demographic factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearDescription: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
Measure: pharmacologic factors and severity of COVID-19 infection Time: through study completion, an average of 2 year